---
title: "Assembly Biosciences, Inc. (ASMB.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ASMB.US.md"
symbol: "ASMB.US"
name: "Assembly Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T15:59:02.658Z"
locales:
  - [en](https://longbridge.com/en/quote/ASMB.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ASMB.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ASMB.US.md)
---

# Assembly Biosciences, Inc. (ASMB.US)

## Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.assemblybio.com](https://www.assemblybio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: B (0.34)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 42 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 121.11% |  |
| Net Profit YoY | 84.01% |  |
| P/B Ratio | 2.10 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 417339886.08 |  |
| Revenue | 71097000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -5.66% | D |
| Profit Margin | -8.98% | D |
| Gross Margin | 100.00% | A |
| Revenue YoY | 121.11% | A |
| Net Profit YoY | 84.01% | A |
| Total Assets YoY | 137.85% | A |
| Net Assets YoY | 631.99% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 121.11% | A |
| Turnover | 0.43 | C |
| Gearing Ratio | 15.67% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Assembly Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "121.11%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "84.01%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.10",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "417339886.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "71097000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-5.66%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-8.98%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "121.11%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "84.01%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "137.85%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "631.99%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "121.11%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.67%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -65.38 | 541/385 | - | - | - |
| PB | 2.10 | 193/385 | 20.47 | 3.22 | 2.34 |
| PS (TTM) | 5.87 | 121/385 | 13.68 | 11.34 | 4.58 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 26.03 |
| Highest Target | 62.00 |
| Lowest Target | 40.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ASMB.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ASMB.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ASMB.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ASMB.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**